Tremelimumab

Resumen

Alternativas con registro en Colombia

• Edrecolomab
• Gemtuzumab Ozogamicina
• Ipilimumab · costo anual estimado $ 1.144.599.485
• Brentuximab Vedotina
• Blinatumomab · costo anual estimado $ 575.343.295
• Enfortumab Vedotina
• Polatuzumab Vedotin · costo anual estimado $ 634.694.850
• Sacituzumab Govitecan · costo anual estimado $ 835.929.935
• Tarlatamab

Estudios clínicos principales

• HIMALAYA: Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
  Fase 3 · 2017 · 1.324 participantes · AstraZeneca · NCT03298451
• POSEIDON: Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
  Fase 3 · 2017 · 1.186 participantes · AstraZeneca · NCT03164616
• Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
  Fase 3 · 2015 · 1.126 participantes · AstraZeneca · NCT02516241
• MYSTIC: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
  Fase 3 · 2015 · 1.118 participantes · AstraZeneca · NCT02453282

Enfermedades relacionadas

• Cáncer (todos)
• Cáncer de pulmón
• Cáncer de hígado

Fuentes

• Etiqueta FDA (DailyMed): IMJUDO
• EMA: Imjudo